NCT00648739View on ClinicalTrials.gov

Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

June 19, 2008

Primary Completion Date

December 14, 2010

Study Completion Date

December 14, 2010

Conditions
B-cell Chronic Lymphocytic LeukemiaMultiple Myeloma
Interventions
DRUG

Samalizumab

Samalizumab is a humanized anti-CD200 monoclonal antibody.

Trial Locations (4)

27710

Durham

30322

Atlanta

85719

Tucson

07962

Morristown

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY